These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 29683226)

  • 21. Nadroparin carries a potentially high risk of inducing cutaneous delayed-type hypersensitivity responses.
    Schindewolf M; Recke A; Zillikens D; Lindhoff-Last E; Ludwig RJ
    Contact Dermatitis; 2017 Jul; 77(1):35-41. PubMed ID: 28294347
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Heparin-induced thrombocytopenia after elective hip joint replacement with postoperative prevention of thromboembolism with low-molecular-weight heparin].
    Marx A; Huhle G; Hoffmann U; Wang LC; Schüle B; Jani L; Harenberg J
    Z Orthop Ihre Grenzgeb; 1999; 137(6):536-9. PubMed ID: 10666863
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The severity of trauma determines the immune response to PF4/heparin and the frequency of heparin-induced thrombocytopenia.
    Lubenow N; Hinz P; Thomaschewski S; Lietz T; Vogler M; Ladwig A; Jünger M; Nauck M; Schellong S; Wander K; Engel G; Ekkernkamp A; Greinacher A
    Blood; 2010 Mar; 115(9):1797-803. PubMed ID: 19965682
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The incidence and clinical features of heparin-induced thrombocytopenia.
    Bartholomew JR
    Semin Hematol; 2005 Jul; 42(3 Suppl 3):S3-8. PubMed ID: 16105557
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Heparin-induced thrombocytopenia.
    Fabris F; Luzzatto G; Stefani PM; Girolami B; Cella G; Girolami A
    Haematologica; 2000 Jan; 85(1):72-81. PubMed ID: 10629596
    [TBL] [Abstract][Full Text] [Related]  

  • 26. No difference in risk for thrombocytopenia during treatment of pulmonary embolism and deep venous thrombosis with either low-molecular-weight heparin or unfractionated heparin: a metaanalysis.
    Morris TA; Castrejon S; Devendra G; Gamst AC
    Chest; 2007 Oct; 132(4):1131-9. PubMed ID: 17646239
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Complications and risks associated with an anticoagulation therapy combining low molecular weight heparin and Warfarin after total replacement of large joints--our experience].
    Míka P; Behounek J; Skoták M; Nevsímal L
    Acta Chir Orthop Traumatol Cech; 2004; 71(4):237-44. PubMed ID: 15456102
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Skin necrosis at the injection site induced by low-molecular-weight heparin: case report and review.
    Santamaría A; Romaní J; Souto JC; López A; Mateo J; Fontcuberta J
    Dermatology; 1998; 196(2):264-5. PubMed ID: 9568422
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Incidence and causes of heparin-induced skin lesions.
    Schindewolf M; Schwaner S; Wolter M; Kroll H; Recke A; Kaufmann R; Boehncke WH; Lindhoff-Last E; Ludwig RJ
    CMAJ; 2009 Oct; 181(8):477-81. PubMed ID: 19786468
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Delayed-type hypersensitivity to low molecular weight heparins and heparinoids: cross-reactivity does not depend on molecular weight.
    Grims RH; Weger W; Reiter H; Arbab E; Kränke B; Aberer W
    Br J Dermatol; 2007 Sep; 157(3):514-7. PubMed ID: 17573880
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Medical and Economic Burden of Heparin-Induced Thrombocytopenia: A Retrospective Nationwide Inpatient Sample (NIS) Study.
    Pathak R; Bhatt VR; Karmacharya P; Aryal MR; Donato AA
    J Hosp Med; 2017 Feb; 12(2):94-97. PubMed ID: 28182804
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The complex clinical picture of side effects to anticoagulation.
    Trautmann A; Seitz CS
    Med Clin North Am; 2010 Jul; 94(4):821-34, xii-iii. PubMed ID: 20609865
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Risk factors for thrombosis in patients with immune mediated heparin-induced thrombocytopenia.
    Fabris F; Luzzatto G; Soini B; Ramon R; Scandellari R; Randi ML; Girolami A
    J Intern Med; 2002 Aug; 252(2):149-54. PubMed ID: 12190890
    [TBL] [Abstract][Full Text] [Related]  

  • 34. How frequently is venous thromboembolism in heparin-treated patients associated with heparin-induced thrombocytopenia?
    Levine RL; McCollum D; Hursting MJ
    Chest; 2006 Sep; 130(3):681-7. PubMed ID: 16963663
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Heparin-induced skin lesions.
    Schindewolf M; Lindhoff-Last E; Ludwig RJ; Boehncke WH
    Lancet; 2012 Nov; 380(9856):1867-79. PubMed ID: 22642893
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anti-platelet factor 4/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin.
    Warkentin TE; Cook RJ; Marder VJ; Sheppard JA; Moore JC; Eriksson BI; Greinacher A; Kelton JG
    Blood; 2005 Dec; 106(12):3791-6. PubMed ID: 16109780
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adverse effects of heparin.
    Alban S
    Handb Exp Pharmacol; 2012; (207):211-63. PubMed ID: 22566227
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Management of cutaneous type IV hypersensitivity reactions induced by heparin.
    Ludwig RJ; Schindewolf M; Utikal J; Lindhoff-Last E; Boehncke WH
    Thromb Haemost; 2006 Nov; 96(5):611-7. PubMed ID: 17080218
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Delayed hypersensitivity at the injection sites of a low-molecular-weight heparin.
    Moreau A; Dompmartin A; Esnault P; Michel M; Leroy D
    Contact Dermatitis; 1996 Jan; 34(1):31-4. PubMed ID: 8789222
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Delayed-type hypersensitivity and cross-reactivity to heparins and danaparoid: a prospective study.
    Grassegger A; Fritsch P; Reider N
    Dermatol Surg; 2001 Jan; 27(1):47-52. PubMed ID: 11231243
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.